Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 7.23
BABY's Cash to Debt is ranked higher than
76% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. BABY: 7.23 )
BABY' s 10-Year Cash to Debt Range
Min: 0.32   Max: No Debt
Current: 7.23

Equity to Asset 0.80
BABY's Equity to Asset is ranked higher than
84% of the 446 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. BABY: 0.80 )
BABY' s 10-Year Equity to Asset Range
Min: -1.79   Max: 0.94
Current: 0.8

-1.79
0.94
Interest Coverage 20.47
BABY's Interest Coverage is ranked higher than
58% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 235.10 vs. BABY: 20.47 )
BABY' s 10-Year Interest Coverage Range
Min: 4.92   Max: 9999.99
Current: 20.47

4.92
9999.99
F-Score: 7
Z-Score: 10.11
M-Score: -2.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.02
BABY's Operating margin (%) is ranked higher than
87% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. BABY: 13.02 )
BABY' s 10-Year Operating margin (%) Range
Min: -32.53   Max: 15.75
Current: 13.02

-32.53
15.75
Net-margin (%) 8.77
BABY's Net-margin (%) is ranked higher than
84% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. BABY: 8.77 )
BABY' s 10-Year Net-margin (%) Range
Min: -27.59   Max: 14.29
Current: 8.77

-27.59
14.29
ROE (%) 9.80
BABY's ROE (%) is ranked higher than
83% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. BABY: 9.80 )
BABY' s 10-Year ROE (%) Range
Min: -18.17   Max: 10.21
Current: 9.8

-18.17
10.21
ROA (%) 7.34
BABY's ROA (%) is ranked higher than
86% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. BABY: 7.34 )
BABY' s 10-Year ROA (%) Range
Min: -11.99   Max: 9
Current: 7.34

-11.99
9
ROC (Joel Greenblatt) (%) 48.03
BABY's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. BABY: 48.03 )
BABY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -130.1   Max: 72.5
Current: 48.03

-130.1
72.5
Revenue Growth (3Y)(%) 14.30
BABY's Revenue Growth (3Y)(%) is ranked higher than
89% of the 340 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. BABY: 14.30 )
BABY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61.8   Max: 38.3
Current: 14.3

-61.8
38.3
EBITDA Growth (3Y)(%) 17.70
BABY's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. BABY: 17.70 )
BABY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -100   Max: 165
Current: 17.7

-100
165
EPS Growth (3Y)(%) 21.80
BABY's EPS Growth (3Y)(%) is ranked higher than
88% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. BABY: 21.80 )
BABY' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.8   Max: 26
Current: 21.8

-52.8
26
» BABY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BABY Guru Trades in Q4 2013

Joel Greenblatt 59,506 sh (New)
Jim Simons 172,274 sh (+958.58%)
Steven Cohen 14,137 sh (+26.46%)
David Nierenberg Sold Out
Diamond Hill Capital 973,300 sh (-3.33%)
Paul Tudor Jones 18,099 sh (-30.39%)
» More
Q1 2014

BABY Guru Trades in Q1 2014

Chuck Royce 2,100 sh (New)
Joel Greenblatt 596,487 sh (+902.4%)
Paul Tudor Jones 26,776 sh (+47.94%)
Steven Cohen Sold Out
Diamond Hill Capital 968,350 sh (-0.51%)
Jim Simons 167,945 sh (-2.51%)
» More
Q2 2014

BABY Guru Trades in Q2 2014

Jim Simons 405,145 sh (+141.24%)
Diamond Hill Capital 969,630 sh (+0.13%)
Chuck Royce Sold Out
Joel Greenblatt 595,883 sh (-0.1%)
Paul Tudor Jones 24,823 sh (-7.29%)
» More
Q3 2014

BABY Guru Trades in Q3 2014

Ken Fisher 548,495 sh (New)
Paul Tudor Jones 25,620 sh (+3.21%)
Diamond Hill Capital 960,470 sh (-0.94%)
Joel Greenblatt 400,972 sh (-32.71%)
Jim Simons 269,045 sh (-33.59%)
» More
» Details

Insider Trades

Latest Guru Trades with BABY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Reduce -32.71%0.06%$24.29 - $29.4 $ 35.6729%400972
Ken Fisher 2014-09-30 New Buy0.04%$24.29 - $29.4 $ 35.6729%548495
Joel Greenblatt 2014-03-31 Add 902.4%0.21%$22.02 - $27.02 $ 35.6742%596487
Joel Greenblatt 2013-12-31 New Buy0.03%$13.61 - $23.03 $ 35.6784%59506
Ken Fisher 2011-12-31 Sold Out 0.02%$7.43 - $9.78 $ 35.67317%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Natus Medical Inc

Diamond Hill Capital Comments on Natus Medical Inc - Oct 17, 2014

Shares of medical device manufacturer Natus Medical, Inc. (BABY) increased after reporting strong quarterly earnings and raising its full-year 2014 earnings guidance. While the company has shown improvement in margins for some time, this was the best quarter of organic revenue growth for Natus in years.

From Diamond Hill Capital (Trades, Portfolio)'s Small Cap Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Natus Medical Inc - Jun 26, 2014

Shares of infant medical device manufacturer Natus Medical, Inc. (BABY) rose as the company reported strong quarterly earnings, continued margin improvement, and a promising outlook for the year.



From Diamond Hill Capital's Small Cap Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Natus Medical Inc

Diamond Hill Capital Comments on Natus Medical Inc
Shares of medical device manufacturer Natus Medical, Inc. (BABY) increased after reporting strong quarterly earnings and raising its full-year 2014 earnings guidance. While the company has shown improvement in margins for some time, this was the best quarter of organic revenue growth for Natus in years. Read more...
Diamond Hill Capital Comments on Natus Medical Inc
Shares of infant medical device manufacturer Natus Medical, Inc. (BABY) rose as the company reported strong quarterly earnings, continued margin improvement, and a promising outlook for the year. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 37.30
BABY's P/E(ttm) is ranked higher than
81% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 84.60 vs. BABY: 37.30 )
BABY' s 10-Year P/E(ttm) Range
Min: 11.47   Max: 723.45
Current: 37.3

11.47
723.45
P/B 3.50
BABY's P/B is ranked higher than
73% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. BABY: 3.50 )
BABY' s 10-Year P/B Range
Min: 0.79   Max: 5.69
Current: 3.5

0.79
5.69
P/S 3.30
BABY's P/S is ranked higher than
70% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. BABY: 3.30 )
BABY' s 10-Year P/S Range
Min: 0.95   Max: 8.5
Current: 3.3

0.95
8.5
PFCF 26.50
BABY's PFCF is ranked higher than
89% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. BABY: 26.50 )
BABY' s 10-Year PFCF Range
Min: 12.65   Max: 556
Current: 26.5

12.65
556
EV-to-EBIT 24.14
BABY's EV-to-EBIT is ranked higher than
82% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 61.55 vs. BABY: 24.14 )
BABY' s 10-Year EV-to-EBIT Range
Min: -2754.6   Max: 409.7
Current: 24.14

-2754.6
409.7
Shiller P/E 95.60
BABY's Shiller P/E is ranked higher than
83% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. BABY: 95.60 )
BABY' s 10-Year Shiller P/E Range
Min: 19.55   Max: 2156
Current: 95.6

19.55
2156
Current Ratio 2.79
BABY's Current Ratio is ranked higher than
71% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. BABY: 2.79 )
BABY' s 10-Year Current Ratio Range
Min: 1.3   Max: 16.01
Current: 2.79

1.3
16.01
Quick Ratio 2.25
BABY's Quick Ratio is ranked higher than
73% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. BABY: 2.25 )
BABY' s 10-Year Quick Ratio Range
Min: 0.91   Max: 15.09
Current: 2.25

0.91
15.09

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 21.68
BABY's Price/Net Current Asset Value is ranked higher than
79% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. BABY: 21.68 )
BABY' s 10-Year Price/Net Current Asset Value Range
Min: 1.22   Max: 1418
Current: 21.68

1.22
1418
Price/Tangible Book 8.23
BABY's Price/Tangible Book is ranked higher than
65% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 6.92 vs. BABY: 8.23 )
BABY' s 10-Year Price/Tangible Book Range
Min: 1.02   Max: 64.5
Current: 8.23

1.02
64.5
Price/DCF (Projected) 2.12
BABY's Price/DCF (Projected) is ranked higher than
88% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. BABY: 2.12 )
BABY' s 10-Year Price/DCF (Projected) Range
Min: 0.79   Max: 10.25
Current: 2.12

0.79
10.25
Price/Median PS Value 1.34
BABY's Price/Median PS Value is ranked higher than
67% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. BABY: 1.34 )
BABY' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 3
Current: 1.34

0.13
3
Price/Graham Number 3.68
BABY's Price/Graham Number is ranked higher than
80% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. BABY: 3.68 )
BABY' s 10-Year Price/Graham Number Range
Min: 1.21   Max: 33.06
Current: 3.68

1.21
33.06
Earnings Yield (Greenblatt) 4.10
BABY's Earnings Yield (Greenblatt) is ranked higher than
81% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. BABY: 4.10 )
BABY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 17.5
Current: 4.1

0.2
17.5
Forward Rate of Return (Yacktman) 9.85
BABY's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 5.52 vs. BABY: 9.85 )
BABY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.5   Max: 75
Current: 9.85

-1.5
75

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:NM4.Germany,
Natus Medical, Inc., was incorporated in California in May 1987 and reincorporated in Delaware in August 2000. The Company is a provider of newborn care and neurology healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The Company offers two product families: Neurology and Newborn Care. Neurology includes products for diagnostic electroencephalography (EEG), electromyography (EMG), diagnostic sleep analysis or polysomnography (PSG), intra-operative monitoring (IOM), and transcranial doppler ultrasound technology. Newborn Care includes products for newborn care including hearing screening, brain injury, thermoregulation, jaundice management, and various disposable products, as well as products for diagnostic hearing assessment for children through adult populations, and products to diagnose and assist in treating balance and mobility disorders. The Company is subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements.
» More Articles for BABY

Headlines

Articles On GuruFocus.com
Diamond Hill Small Cap Fund Third Quarter Letter Oct 25 2014 
Diamond Hill Capital Comments on Natus Medical Inc Oct 17 2014 
Diamond Hill Small Cap Fund Third Quarter 2014 Commentary Oct 17 2014 
Diamond Hill Capital Comments on Natus Medical Inc Jun 26 2014 
Diamond Hill Small Cap Fund Commentary – First Quarter 2014 Jun 25 2014 
Weekly CEO Sells Highlight: OCZ Technology Group Inc, Workday Inc, Gilead Sciences Inc, Natus Medica Dec 09 2013 
Natus Medical Inc. Reports Operating Results (10-Q) Nov 05 2010 
David Nierenberg’s Top Holdings: MOVE, ESIO, BABY, RSYS, HPY, SPN Aug 27 2010 
Natus Medical Inc. (BABY) VP Finance and CFO Steven J Murphy sells 1,814 Shares Aug 19 2010 
Natus Medical Inc. (BABY) President and CEO James B Hawkins sells 6,796 Shares Aug 19 2010 

More From Other Websites
Natus Medical (BABY) Hits 52-Week High on Bullish Trends Dec 10 2014
Strong And Under The Radar: Natus Medical (BABY) Nov 21 2014
NATUS MEDICAL INC Financials Nov 14 2014
10-Q for Natus Medical, Inc. Nov 07 2014
NATUS MEDICAL INC Files SEC form 10-Q, Quarterly Report Nov 05 2014
Edwards Lifesciences (EW) Worth Watching: Stock Up 11% Oct 27 2014
Today Natus Medical (BABY) Hits New Lifetime High Oct 24 2014
Natus Medical Inc Earnings Call scheduled for 11:00 am ET today Oct 22 2014
Natus Medical tops Street 3Q forecasts Oct 22 2014
Natus Medical tops Street 3Q forecasts Oct 22 2014
Natus Medical Announces Record Third Quarter and Year-to-Date 2014 Financial Results Oct 22 2014
NATUS MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Oct 22 2014
Q3 2014 Natus Medical Inc Earnings Release - Before Market Open Oct 22 2014
Natus Medical Announces Record Third Quarter and Year-to-Date 2014 Financial Results Oct 22 2014
Don't Miss Today's Strong And Under The Radar Stock: Natus Medical (BABY) Oct 21 2014
Market Thorns, Roses, and All Time Highs... Oct 16 2014
Natus Medical Announces First of Kind Vista Ultrasound System Oct 16 2014
Natus Medical Announces First of Kind Vista Ultrasound System Oct 16 2014
Natus Medical to Hold 2014 Third Quarter Financial Results Conference Call on October 22nd Oct 08 2014
Sirona's EPS Growth Accelerates On Instrument Sales Aug 08 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK